{"id":"W2891651027","doi":"10.1200/jco.2018.36.15_suppl.8566","title":"Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Placebo; Gastroenterology; Clinical endpoint; Pemetrexed; Confidence interval; Combination therapy; Phases of clinical research; Progression-free survival; Surgery; Urology; Chemotherapy; Randomized controlled trial; Cisplatin; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003431236,0.0006697007,0.001281634,0.0003248178,0.0001621285,0.0004857516,0.0005536154,0.0006896014,0.001602469],"category_scores_gemma":[0.003073841,0.0005532665,0.001942566,0.0003950067,0.0003381736,0.000549097,0.0004904299,0.001127035,0.0001781153],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005604249,"about_ca_system_score_gemma":0.0006628133,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007908515,"about_ca_topic_score_gemma":0.001374657,"domain_scores_codex":[0.998881,0.0007816591,0.00004657026,0.0001221387,0.00008122928,0.00008744766],"domain_scores_gemma":[0.9981847,0.0007530314,0.0006588383,0.0001299234,0.00004137934,0.0002319514],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.831174,0.005551225,0.09891616,0.0007955194,0.005306101,0.0001295236,0.0001350269,0.004274622,0.00833593,0.0001043129,0.0005552344,0.04472231],"study_design_scores_gemma":[0.1041502,0.3282328,0.5340196,0.0001091971,0.01004486,0.0003805854,0.0001096759,0.01604148,0.004165651,0.0004712025,0.002203401,0.00007131292],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972042,0.001684531,0.0003872868,0.00008395826,0.00002145617,0.0001257393,0.0002442387,0.00001689091,0.0002316359],"genre_scores_gemma":[0.9985777,0.0003427574,0.0003082583,0.0000630028,0.00003722987,0.0001442036,0.0002313041,0.000003521848,0.0002919411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003431236,"threshold_uncertainty_score":0.01814628,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04242951230717217,"score_gpt":0.3757143092792937,"score_spread":0.3332847969721215,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}